ALCLS (ALCLS) News
Follow ALCLS (ALCLS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Cellectis Price Target Cut to $3.00/Share From $4.00 by Wells Fargo
Ratings actions from Benzinga: GMT) Cellectis Is Maintained at Equal-Weight by Wells FargoRatings actions from Benzinga
NEWS | Sep 15, 2026, 12:53 PM UTC
L
Cellectis Is Maintained at Outperform by Baird
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 12:52 PM UTC
L
Cellectis Cut to Market Perform From Market Outperform by Citizens
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 12:40 PM UTC
L
CLLS Stock Heads For 14-Month Low After 40% Rout: Citizens Flags Delayed Cellectis Catalysts After Cancer Pipeline Pivot
Cellectis (CLLS) remained on investors’ radar on Tuesday as the biotech firm received a downgrade from Citizens after it stopped further development of its lead blood-cancer treatments and shifted its focus toward cardio
EQUITY | Sep 15, 2026, 11:17 AM UTC
L
Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cel
NEWS | Sep 11, 2026, 08:34 PM UTC
L
Cellectis files monthly capital and voting rights information
Cellectis published monthly information on share capital and company voting rights for its Euronext Growth listing. The release references Article 223-16 of the French financial markets authority General Regulation.
EQUITY | Sep 03, 2026, 08:37 PM UTC
L
Cellectis to participate in upcoming investor conferences
Cellectis said it will participate in upcoming investor conferences. The Company is listed on Euronext Growth under ALCLS and on NASDAQ as CLLS.
EQUITY | Sep 01, 2026, 08:37 PM UTC